Literature DB >> 7508442

Consensus repeat domains of E-selectin enhance ligand binding.

S H Li1, D K Burns, J M Rumberger, D H Presky, V L Wilkinson, M Anostario, B A Wolitzky, C R Norton, P C Familletti, K J Kim.   

Abstract

To study the structural characteristics of E-selectin necessary for mediating cell adhesion, we examined the role of the consensus repeat (CR) domains in E-selectin function. Soluble constructs containing different numbers of CR domains were stably expressed in Chinese hamster ovary cells, purified to homogeneity, and characterized. The minimum functional unit of soluble E-selectin consisted of the lectin (Lec) and epidermal growth factor (EGF) domains alone (Lec-EGF) as indicated by its ability to mediate in vitro HL-60 cell adhesion. However, E-selectin containing all six CR domains (Lec-EGF-CR6) at its COOH terminus was the most potent in blocking neutrophil or HL-60 cell adhesion to either immobilized E-selectin or cytokine-stimulated human umbilical vein endothelial cells. This increased potency of Lec-EGF-CR6 in blocking cell adhesion was not due to CR-mediated oligomerization of the protein. Lec-EGF-CR6 was most likely monomeric in solution, as judged by gel filtration fast protein liquid chromatography, membrane ultrafiltration, and chemical cross-linking analysis. Therefore, although the lectin and EGF domains are necessary and sufficient for mediating cell adhesion, the additional six CR domains, present in native E-selectin, contribute to the enhanced binding of E-selectin to its ligand.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508442

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Implications of the E-selectin S128R mutation for drug discovery.

Authors:  Roland C Preston; Said Rabbani; Florian P C Binder; Suzette Moes; John L Magnani; Beat Ernst
Journal:  Glycobiology       Date:  2014-03-31       Impact factor: 4.313

Review 2.  Selectin ligands.

Authors:  A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

3.  Determining force dependence of two-dimensional receptor-ligand binding affinity by centrifugation.

Authors:  J W Piper; R A Swerlick; C Zhu
Journal:  Biophys J       Date:  1998-01       Impact factor: 4.033

4.  Mapping the epitope of a functional P-selectin monoclonal antibody (LYP20) to a short complement-like repeat (SCR 4) domain: use of human-mouse chimaera and homologue-replacement mutagenesis.

Authors:  M H Ruchaud-Sparagano; E Malaud; O Gayet; E Chignier; R Buckland; J L McGregor
Journal:  Biochem J       Date:  1998-06-01       Impact factor: 3.857

5.  Selectin ligands on human melanoma cells.

Authors:  N Miller; R G Vile; I R Hart
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

6.  Probabilistic modeling of rosette formation.

Authors:  Mian Long; Juan Chen; Ning Jiang; Periasamy Selvaraj; Rodger P McEver; Cheng Zhu
Journal:  Biophys J       Date:  2006-04-07       Impact factor: 4.033

7.  Intrinsic disorder in biomarkers of insulin resistance, hypoadiponectinemia, and endothelial dysfunction among the type 2 diabetic patients.

Authors:  Osama H Al-Jiffri; Fadwa M Al-Sharif; Essam H Al-Jiffri; Vladimir N Uversky
Journal:  Intrinsically Disord Proteins       Date:  2016-05-11

8.  Porcine E-selectin: cloning and functional characterization.

Authors:  Y T Tsang; P E Stephens; S T Licence; D O Haskard; R M Binns; M K Robinson
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

9.  Expression, purification, and refolding of active recombinant human E-selectin lectin and EGF domains in Escherichia coli.

Authors:  Susumu Kawano; Daisuke Iyaguchi; Chiaki Okada; Yusuke Sasaki; Eiko Toyota
Journal:  Protein J       Date:  2013-06       Impact factor: 2.371

Review 10.  Targeting selectins and selectin ligands in inflammation and cancer.

Authors:  Steven R Barthel; Jacyln D Gavino; Leyla Descheny; Charles J Dimitroff
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.